 |
 |
 |
 |
 |
November
2009: VOLUME
2, NUMBER 2
Safety of Biologic Agents
In this Issue...
In this issue, we review several articles highlighting the safety of and screening measures for biologic agents used in patients with skin disease. Although these therapies provide a promising alternative to such older treatments as methotrexate, cyclosporine, and ultraviolet (UV) radiation, they are still relatively new to the market and long-term studies on their risk profiles are ongoing. Additional information on the safety, efficacy, and screening requirements for biologic therapies will become available as more practitioners incorporate them into their clinical practice.
- Commentary from our Guest Authors
- Long-Term Safety and Efficacy of Etanercept in Patients With Psoriasis Treatments and the Risk for Malignancy
- Screening and Monitoring of Patients Taking Biologic Agents for the Treatment of Psoriasis
- Tuberculosis Screening and Biologic Agents Presentation and Management of Tuberculosis in Patients Undergoing Biologic Therapy
|
|
 |
|
 |
 |
 |
At
the conclusion of this activity, participants should be able
to:
 |
 |
Identify specific risks associated with use of the new biologic therapies. |
 |
 |
 |
Describe tuberculosis in the setting of biologic therapy, including screening requirements, necessary treatment for latent infection, and recognition of active disease. |
 |
 |
 |
Evaluate the current screening and safety testing that should be performed in patients prior to and while undergoing biologic therapy. |
  |
 |
|
  |
 |
 |
IMPORTANT CME/CNE INFORMATION |
 |
|
|
 |
 |
 |
accreditation statements
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
credit designations
Physicians
The Johns Hopkins University School
of Medicine designates this educational activity
for a maximum of 1.0 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Nurses
This 1.0 contact hour Educational Activity is provided by The Institute for Johns Hopkins Nursing. Each Newsletter carries a maximum of 1 contact hours.
post-test
To take the post-test for eMedicalDermatology Review you will need to visit The Johns Hopkins University School of Medicine's CME website or The Institute for Johns Hopkins Nursing. If you have already registered for another Hopkins CME program at these sites, simply enter the requested information when prompted. Otherwise, complete the registration form to begin the testing process. A passing grade of 70% or higher on the post test/evaluation is required to receive CME/CNE credit.
statement of responsibility
The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.
intended audience
This activity has been developed for the Dermatologist, Nurses, Dermasurgeon, Dermatopathologist, Pediatric Dermatologist, Immunodermatologist, Wound Care Specialist and Allied Healthcare providers.
faculty disclosure
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Directors reported the following:
|
 |
 |
|
 |
 |
 |
 |
Bernard A. Cohen, MD, has indicated he has received grants for studies from Novartis Pharmaceuticals and Astellas Pharma Inc. |
 |
 |
Susan Matra Rabizadeh, MD, MBA has disclosed no relationship with commercial supporters. |
 |
 |
Mark Lebwohl, MD has disclosed that he has received grants for clinical research, Advisory Board, speaker honorarium for/from Abbott, Amgen/Wyeth, Astellas, Centocor, Galderma, Genentech, Novartis, GlaxoSmithKline, Triax, Warner Chilcott. Serving as a consultant and receiving honorarium for/from Actelion, Cerexa, DermiPsor, Electro Optical Sciences, Helix BioMedix, Magen Biosciences, NeoStrata, Peplin, Sanofi-Aventis, Taro, Graceway and Pharmaderm. Advisory Board and receiving honorarium for/from Medicis, Nycomed and Pfizer. Speaker honorarium from Ranbaxy. |
 |
 |
Elizabeth Sloand, PhD, CRNP has disclosed no relationships with commercial supporters. |
 |
 |
Guest
Author’s Disclosures |
Launch date
This program launched on September 22, 2009 and is published bi-monthly; activities expire 2 years from the date of publication, ending in May 2012.
internet cme/ce policy
The Offices of Continuing Education (CE) at The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing are committed to protect the privacy of its members and customers. The Johns Hopkins University maintains its Internet site as an information resource and service for physicians, other health professionals and the public.
The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing will keep your personal and credit information confidential when you participate in a CE Internet based program. Your information will never be given to anyone outside The Johns Hopkins University program. CE collects only the information necessary to provide you with the service you request.
disclaimer statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
hardware & software requirements
Pentium 800 processor or greater, Windows 98/NT/2000/XP or Mac OS 9/X, Microsoft Internet Explorer 5.5 or later, 56K Modem or better, Windows Media Player 9.0 or later, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader. |
 |
 |
|
|
|
|
|
 |
|
  |
 |
 |
|
 |
Program
Directors
Bernard
A. Cohen, MD
Professor of Pediatrics and Dermatology and Director
of Pediatric Dermatology,
Johns Hopkins Children’s Center
Baltimore, MD
Susan
Matra Rabizadeh, MD, MBA
Department of Dermatology
Cedars-Sinai Medical Group
Beverly Hills, CA
Mark
Lebwohl, MD
Professor and Chairman
Department of Dermatology
The Mount Sinai School of Medicine
New York, NY
Elizabeth
Sloand, PhD, CRNP
Assistant Professor of Pediatric Nursing
The Johns Hopkins University
School of Nursing
Baltimore, MD |
|
|
 |
 |
 |
 |
GUEST
AUTHORS OF THE MONTH |
|
 |
 |
 |
 |
 |
Commentary
& Reviews: |
|
Boni E. Elewski, MD
Professor of Dermatology
University of Alabama at Birmingham
Department of Dermatology
Birmingham, AL |
 |
 |
Commentary
& Reviews: |
|
Shelley Cathcart, MD
Dermatology Resident
University of Alabama at Birmingham
Department of Dermatology
Birmingham, AL |
|
 |
Guest
Faculty Disclosures
Boni Elewski, MD has disclosed that she has received grants for clinical research for/from Abbott, Amgen/Wyeth and Centocor.
Shelley Cathcart, MD discloses that she has no financial relationship with commercial supporters.
Unlabeled/Unapproved Uses
The authors have indicated that there will be no reference to unlabeled or unapproved uses of drugs or products in this presentation.
Program
Directors’ Disclosures |
|
|
 |
|
 |
 |
|
 |
 |
 |
TO COMPLETE
THE
POST-TEST
Step
1.
Please read the newsletter.
Step
2.
See the Post-test link at the end of the newsletter.
Step
3.
Follow the instructions to access the post-test.
|
 |
 |
|
 |
|